Breast Cancer Liquid Biopsy Market Size Worth $2,700.76 Million By 2034 | CAGR: 20.8%
The global breast cancer liquid biopsy market size is expected to reach USD 2,700.76 million by 2034, according to a new study by Polaris Market Research. The report, “Breast Cancer Liquid Biopsy Market Size, Share & Trends Analysis Report: By Product Type, By Circulating Biomarker, By Technology, By Application, By Indication, By End User, By Region – Market Forecast, 2026–2034” analyzes market trends, growth drivers, segment performance, regional developments, and competitive dynamics.
Breast cancer liquid biopsy uses blood samples to analyze tumor-derived biomarkers, including circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), and circulating tumor cells (CTCs). These tests can identify genetic changes, help to determine treatment options and monitor disease progression. The growing demand for non-invasive cancer diagnostics, advancement in genomic profiling, and utilization of liquid biopsy in precision oncology are providing opportunities in breast cancer diagnosis and treatment monitoring.
Do you have any questions? Would you like to request a sample or make an inquiry before purchasing this report? Simply click the link below: Breast Cancer Liquid Biopsy Market Report
Technological advancements in circulating tumor DNA analysis, next-generation sequencing and molecular residual disease (MRD) testing drive market growth for breast cancer liquid biopsy. These technologies help identify actionable mutations and monitor treatment response through blood-based testing. Opportunities include early detection, targeted therapy selection, monitoring recurrence, and personalized cancer care.
Major trends in the breast cancer liquid biopsy market include ctDNA testing and MRD monitoring. Targeted treatments also come with companion diagnostics to identify eligible patients based on the detection of specific genetic alterations like ESR1 and PIK3CA mutations. Diagnostic companies are working on advanced assays and clinical applications to enhance molecular profiling and treatment monitoring in breast cancer.
Small Molecule CDMO Market Report Highlights
- The ctDNA/cfDNA segment accounted for 42.54% of the breast cancer liquid biopsy market share in 2025, driven by demand for blood-based mutation testing.
- In 2025, the NGS segment dominated with 63.90% share, due to its application in multi-gene profiling.
- North America held a 37.78% share of the global market in 2025, supported by the well-established infrastructure for oncology diagnostics and access to sophisticated testing.
- The Asia Pacific market is expected to register the highest CAGR of 22.69% from 2026 to 2034, due to increasing cancer diagnostic services and rising adoption of precision medicine.
- A few of the prominent companies operating in the breast cancer liquid biopsy market include Abbott Laboratories, F. Hoffmann-La Roche Ltd., Guardant Health, Illumina, Inc., Menarini Group, Myriad Genetics, Inc., Natera, Inc., NeoGenomics, Inc., Personalis, Inc., QIAGEN N.V., SAGA Diagnostics, and Thermo Fisher Scientific Inc.
The breast cancer liquid biopsy market is segmented on the basis of product type, circulating biomarker, technology, application, indication, end user, and region:
By Product Outlook (Revenue, USD Million, 2021–2034)
- Assay Kits & Reagents
- Instruments
- Services
By Circulating Biomarker Outlook (Revenue, USD Million, 2021–2034)
- Circulating Tumor Cells (CTCs)
- Cell-Free DNA/Circulating Tumor DNA (cfDNA/ctDNA)
- Extracellular Vesicles
- Other Circulating Biomarkers
By Technology Outlook (Revenue, USD Million, 2021–2034)
- Next-Generation Sequencing (NGS)
- PCR/Digital PCR
- Circulating Tumor Cell (CTC) Enrichment
- Others
By Application Outlook (Revenue, USD Million, 2021–2034)
- Early Detection & Screening
- Diagnosis
- Treatment Selection
- Monitoring
By Indication Outlook (Revenue, USD Million, 2021–2034)
- HR-Positive/HER2-Negative (HR+/HER2−)
- HER2-Positive
- Triple-Negative Breast Cancer (TNBC)
- Early-Stage and Metastatic Disease
By End User Outlook (Revenue, USD Million, 2021–2034)
- Hospitals
- Specialty Clinics
- Diagnostic Laboratories
- Homecare
By Region Outlook (Revenue – USD Million, 2021–2034)
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Netherlands
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Indonesia
- Australia
- Malaysia
- Rest of Asia Pacific
- Latin America
- Argentina
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- UAE
- Saudi Arabia
- Israel
- South Africa
- Rest of Middle East & Africa